LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 75

Search options

  1. Article ; Online: Pulsed dye laser treatment of superficial basal cell carcinoma.

    Sheehan-Dare, R

    The British journal of dermatology

    2015  Volume 172, Issue 3, Page(s) 557–558

    MeSH term(s) Carcinoma, Basal Cell/surgery ; Female ; Humans ; Lasers, Dye/therapeutic use ; Male ; Skin Neoplasms/surgery
    Language English
    Publishing date 2015-03
    Publishing country England
    Document type Comment ; Journal Article
    ZDB-ID 80076-4
    ISSN 1365-2133 ; 0007-0963
    ISSN (online) 1365-2133
    ISSN 0007-0963
    DOI 10.1111/bjd.13657
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Lesion-directed treatment for actinic keratoses.

    Sheehan-Dare, R

    The British journal of dermatology

    2014  Volume 170, Issue 5, Page(s) 1012–1013

    MeSH term(s) Cryotherapy/methods ; Facial Dermatoses/therapy ; Female ; Humans ; Keratosis, Actinic/therapy ; Lasers, Gas/therapeutic use ; Male ; Scalp Dermatoses/therapy
    Language English
    Publishing date 2014-05
    Publishing country England
    Document type Comment ; Journal Article
    ZDB-ID 80076-4
    ISSN 1365-2133 ; 0007-0963
    ISSN (online) 1365-2133
    ISSN 0007-0963
    DOI 10.1111/bjd.13044
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: 64

    Wong, Keith / Sheehan-Dare, Gemma / Nguyen, Andrew / Ho, Bao / Liu, Victor / Lee, Jonathan / Brown, Lauren / Dear, Rachel / Chan, Lyn / Sharma, Shikha / Malaroda, Alessandra / Smith, Isabelle / Lim, Elgene / Emmett, Louise

    Pharmaceuticals (Basel, Switzerland)

    2022  Volume 15, Issue 7

    Abstract: Breast cancers are most frequently oestrogen receptor (ER) and progesterone receptor (PR) positive and [18F]Fluorodeoxyglucose PET-CT (FDG) has lower sensitivity for these subtypes. The gastrin-releasing peptide receptor (GRPR) is overexpressed in ER+/PR+ ...

    Abstract Breast cancers are most frequently oestrogen receptor (ER) and progesterone receptor (PR) positive and [18F]Fluorodeoxyglucose PET-CT (FDG) has lower sensitivity for these subtypes. The gastrin-releasing peptide receptor (GRPR) is overexpressed in ER+/PR+ breast cancers. This study assessed the safety and potential of [64Cu]Cu-Sarcophagine (SAR)-Bombesin PET/CT (BBN) in re-staging metastatic ER+/PR+/human epidermal growth-factor-2-negative (HER2-) breast cancer. Seven patients with metastatic ER+/PR+/HER2- breast cancer undergoing staging underwent [64Cu]Cu-SAR-BBN PET-CT. Bloods, vital signs and electrocardiogram, blood tracer-clearance and dosimetry were undertaken. GRPR status was assessed in available metastatic biopsy samples. Staging with conventional imaging ([18F]FDG, bone scan and diagnostic CT) was within 3 weeks of [64Cu]Cu-SAR-BBN PET/CT. PET scans were assessed visually and quantitatively. Seven patients underwent imaging. One of the seven had de-novo metastatic breast cancer and six of the seven recurrent metastatic disease. Two of the seven had lobular subtype. No adverse events were reported. All seven patients were positive on conventional imaging (six of seven on FDG). [64Cu]Cu-SAR-BBN imaging was positive in five of the seven. Both [64Cu]Cu-SAR-BBN-negative patients had disease identified on [18F]FDG. One patient was [64Cu]Cu-SAR-BBN positive/[18F]FDG negative. Four of seven patients were [64Cu]Cu-SAR-BBN positive/[18F]FDG positive. In these four, mean SUVmax was higher for [64Cu]Cu-SAR-BBN than [18F]FDG (SUVmax 15 vs. 12). In the classical lobular subtype (two of seven), [64Cu]Cu-SAR-BBN was more avid compared to [18F]FDG (SUVmax 20 vs. 11, and 20 vs. <3). Dosimetry calculations estimated whole-body effective dose for 200 MBq of [64Cu]Cu-SAR-BBN to be 1.9 mSv. [64Cu]Cu-SAR-BBN PET/CT appears safe and may have diagnostic value in metastatic ER+/PR+/HER2- breast cancer, particularly the lobular subtype. Further evaluation is warranted.
    Language English
    Publishing date 2022-06-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph15070772
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Diagnostic value of

    Nguyen, Andrew / Fullard, Karen / Sheehan-Dare, Gemma / Tang, Reuben / Chan, Lyn / Ho, Bao / Dear, Rachel / Keane, Joanne / Hickey, Adam / Nandurkar, Rohan / Chen, Julia / Chen, Andrew / Lim, Elgene / Emmett, Louise

    Journal of medical imaging and radiation oncology

    2021  Volume 66, Issue 6, Page(s) 731–737

    Abstract: Introduction: 18: Methods: Patients with clinically progressive metastatic ER: Results: Ten women (mean age 57 years) underwent imaging. 8/10 demonstrated disease on both DOTA and FDG. 2/10 positive on conventional imaging, but DOTA: Conclusion!# ...

    Abstract Introduction: 18
    Methods: Patients with clinically progressive metastatic ER
    Results: Ten women (mean age 57 years) underwent imaging. 8/10 demonstrated disease on both DOTA and FDG. 2/10 positive on conventional imaging, but DOTA
    Conclusion: Whilst we have not demonstrated DOTA to be superior to FDG in staging of ER
    MeSH term(s) Breast Neoplasms/diagnostic imaging ; Female ; Fluorodeoxyglucose F18 ; Gallium Radioisotopes ; Humans ; Middle Aged ; Organometallic Compounds ; Pilot Projects ; Positron Emission Tomography Computed Tomography/methods ; Positron-Emission Tomography ; Prospective Studies ; Radionuclide Imaging ; Radiopharmaceuticals ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Tomography, X-Ray Computed
    Chemical Substances Gallium Radioisotopes ; Organometallic Compounds ; Radiopharmaceuticals ; Receptors, Estrogen ; Receptors, Progesterone ; copper dotatate CU-64 ; Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2021-10-21
    Publishing country Australia
    Document type Journal Article
    ZDB-ID 2389687-5
    ISSN 1754-9485 ; 1440-1673 ; 1754-9477 ; 0004-8461
    ISSN (online) 1754-9485 ; 1440-1673
    ISSN 1754-9477 ; 0004-8461
    DOI 10.1111/1754-9485.13342
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: The use of lasers in dermatology.

    Sheehan-Dare, R A

    Hospital medicine (London, England : 1998)

    2001  Volume 62, Issue 1, Page(s) 14–17

    Abstract: There are now a range of lasers capable of effective treatment of vascular, pigmented and other skin lesions with a high degree of selectivity. Understanding the complex interactions between laser irradiation and often diverse lesion morphology is the ... ...

    Abstract There are now a range of lasers capable of effective treatment of vascular, pigmented and other skin lesions with a high degree of selectivity. Understanding the complex interactions between laser irradiation and often diverse lesion morphology is the key to determining the appropriateness of treatment.
    MeSH term(s) Hair Removal/methods ; Hemoglobins/radiation effects ; Humans ; Laser Coagulation/methods ; Melanins/radiation effects ; Port-Wine Stain/surgery ; Telangiectasis/surgery ; Treatment Outcome
    Chemical Substances Hemoglobins ; Melanins
    Language English
    Publishing date 2001-01
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 604229-6
    ISSN 1462-3935 ; 0007-1064
    ISSN 1462-3935 ; 0007-1064
    DOI 10.12968/hosp.2001.62.1.1498
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: A comparative study of a 595-nm with a 585-nm pulsed dye laser in refractory port wine stains.

    Yung, A / Sheehan-Dare, R

    The British journal of dermatology

    2005  Volume 153, Issue 3, Page(s) 601–606

    Abstract: Background: The pulsed dye laser (PDL) is the treatment of choice for port wine stains (PWS); however, some patients' PWS become refractory to further treatments. Technological advances have enabled new machines with the advent of surface cooling ... ...

    Abstract Background: The pulsed dye laser (PDL) is the treatment of choice for port wine stains (PWS); however, some patients' PWS become refractory to further treatments. Technological advances have enabled new machines with the advent of surface cooling devices to deliver longer wavelengths and higher fluence more safely. These advances have the potential to achieve improved response rates in refractory PWS. There are few studies comparing the efficacy of standard PDL treatments for refractory PWS with the wider choice of treatment variables available from newer PDL machines.
    Objectives: To determine if there is any advantage of using a longer wavelength (595 nm) and pulse widths (1.5 ms, 6 ms and 20 ms) over conventional PDL settings (wavelength 585 nm, pulse width 1.5 ms) in refractory PWS.
    Methods: Eighteen consecutive consenting patients with Fitzpatrick skin types 1-4 with a mean age 35 years (range 17-59 years) with refractory PWS were treated routinely with three separate test areas using 595-nm PDL (using three different pulse width settings of 1.5 ms, 6 ms and 20 ms), compared with test areas treated with 585-nm PDL (pulse width 1.5 ms). All test areas were treated with an identical fluence (15 J cm(-2)), spot size (7 mm) and cooling setting (dynamic cooling 60 ms, delay 60 ms).
    Results: We found a statistically significant advantage of 595-nm PDL (pulse width 1.5 ms) over 595-nm PDL (pulse width 6 ms) (P < 0.05) in the treatment of refractory PWS; however, we found no significant advantage using longer pulse widths of 20 ms compared with 1.5 ms with the 595-nm PDL. There was no statistically significant advantage in using a 595-nm PDL over a 585-nm PDL using identical pulse widths of 1.5 ms, spot size, fluence and cryogen cooling settings; however, the number of directly comparable test areas was smaller. Some individual patients in our study obtained a better response with certain 595-nm PDL settings (pulse width 1.5 ms and 6 ms) compared with 585-nm PDL (pulse width 1.5 ms).
    Conclusions: Our experience of high fluence PDL in the treatment of refractory PWS suggests patients treated with 585 nm (pulse width 1.5 ms) improve to a similar degree as patients treated with 595-nm PDL (pulse width 1.5 ms). However, the use of the 595-nm PDL with longer pulse widths yields no extra advantage. For those patients who have failed to improve with high-fluence 585-nm PDL (pulse width 1.5 ms), test areas using 595-nm PDL (pulse width 1.5 ms and 6 ms) should be undertaken to ascertain if individual patients may benefit from the longer pulse width 595-nm PDL.
    MeSH term(s) Adolescent ; Adult ; Female ; Follow-Up Studies ; Humans ; Low-Level Light Therapy/methods ; Male ; Middle Aged ; Port-Wine Stain/radiotherapy ; Prospective Studies ; Radiotherapy Dosage ; Treatment Outcome
    Language English
    Publishing date 2005-09
    Publishing country England
    Document type Comparative Study ; Journal Article
    ZDB-ID 80076-4
    ISSN 1365-2133 ; 0007-0963
    ISSN (online) 1365-2133
    ISSN 0007-0963
    DOI 10.1111/j.1365-2133.2005.06707.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis.

    Fairhurst, D A / Sheehan-Dare, R

    Clinical and experimental dermatology

    2009  Volume 34, Issue 3, Page(s) 421–422

    MeSH term(s) Antibodies, Monoclonal/adverse effects ; Dermatologic Agents/adverse effects ; Female ; Hepatitis, Autoimmune/etiology ; Humans ; Infliximab ; Psoriasis/drug therapy ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Young Adult
    Chemical Substances Antibodies, Monoclonal ; Dermatologic Agents ; Tumor Necrosis Factor-alpha ; Infliximab (B72HH48FLU)
    Language English
    Publishing date 2009-04
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 195504-4
    ISSN 1365-2230 ; 0307-6938
    ISSN (online) 1365-2230
    ISSN 0307-6938
    DOI 10.1111/j.1365-2230.2008.03088.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Admixed desmoplastic trichoepithelioma and benign melanocytic naevi.

    Fairhurst, D A / Merchant, W / Sheehan-Dare, R

    Journal of the European Academy of Dermatology and Venereology : JEADV

    2008  Volume 22, Issue 3, Page(s) 386–387

    MeSH term(s) Adult ; Biopsy ; Carcinoma/diagnosis ; Carcinoma/etiology ; Carcinoma/pathology ; Female ; Humans ; Middle Aged ; Nevus, Pigmented/complications ; Nevus, Pigmented/diagnosis ; Nevus, Pigmented/pathology ; Skin/pathology ; Skin Neoplasms/diagnosis ; Skin Neoplasms/etiology ; Skin Neoplasms/pathology
    Language English
    Publishing date 2008-03
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 1128828-0
    ISSN 1468-3083 ; 0926-9959
    ISSN (online) 1468-3083
    ISSN 0926-9959
    DOI 10.1111/j.1468-3083.2007.02339.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris.

    Langner, A / Sheehan-Dare, R / Layton, A

    Journal of the European Academy of Dermatology and Venereology : JEADV

    2007  Volume 21, Issue 3, Page(s) 311–319

    Abstract: Background: Antibiotics are often combined with other agents to provide topical acne treatments that are effective against both inflammatory and non-inflammatory lesions and minimize the development of antibiotic resistance.: Objectives: To compare ... ...

    Abstract Background: Antibiotics are often combined with other agents to provide topical acne treatments that are effective against both inflammatory and non-inflammatory lesions and minimize the development of antibiotic resistance.
    Objectives: To compare the clinical effectiveness of two combination treatments for facial acne: a ready mixed, once daily gel containing clindamycin phosphate (1%) plus benzoyl peroxide (5%) (CDP + BPO) and a twice daily solution of erythromycin (4%) plus zinc acetate (1.2%) (ERY + Zn).
    Methods/patients: In this assessor-blind, randomized study, 73 patients were treated with CDP + BPO once daily and 75 patients with ERY + Zn twice daily. The treatment period was 12 weeks and lesion counts and global improvement were assessed at weeks 1, 2, 4, 8 and 12.
    Results: CDP + BPO showed an earlier onset of action with a faster significant reduction in total lesion counts than ERY + Zn. The proportion of patients with at least a 30% improvement in non-inflammatory lesions at week 1 was 31.5% for CDP + BPO and 17.3% for ERY + Zn; the corresponding percentages for inflammatory lesions were 39.7% and 29.3%. A difference was also observed at week 2 (53.4% vs. 36.0% for non-inflammatory lesions and 72.6% vs. 53.3% for inflammatory lesions). The trend in favour of CDP + BPO, although less marked, continued to the end of the study, with reductions in the total lesion count at endpoint of 69.8% for CDP + BPO group and 64.5% for ERY + Zn group. Both treatments were well tolerated.
    Conclusions: CDP + BPO and ERY + Zn are effective treatments for acne but CDP + BPO has an earlier onset of action that should improve patient compliance.
    MeSH term(s) Acne Vulgaris/drug therapy ; Administration, Topical ; Adolescent ; Adult ; Anti-Bacterial Agents/administration & dosage ; Benzoyl Peroxide/administration & dosage ; Child ; Clindamycin/administration & dosage ; Decanoic Acids/administration & dosage ; Dermatologic Agents/administration & dosage ; Drug Combinations ; Erythromycin/administration & dosage ; Facial Dermatoses/drug therapy ; Female ; Gels ; Humans ; Male ; Single-Blind Method ; Statistics, Nonparametric ; Treatment Outcome ; Zinc Acetate/administration & dosage
    Chemical Substances Anti-Bacterial Agents ; Decanoic Acids ; Dermatologic Agents ; Drug Combinations ; Gels ; clindamycin phosphate benzoyl peroxide combination ; erythromycin, zinc acetate drug combination ; Clindamycin (3U02EL437C) ; Erythromycin (63937KV33D) ; Zinc Acetate (FM5526K07A) ; Benzoyl Peroxide (W9WZN9A0GM)
    Language English
    Publishing date 2007-03
    Publishing country England
    Document type Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1128828-0
    ISSN 1468-3083 ; 0926-9959
    ISSN (online) 1468-3083
    ISSN 0926-9959
    DOI 10.1111/j.1468-3083.2006.01884.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Pulsed dye laser and intralesional bleomycin for treatment of resistant viol hand warts.

    Pollock, B / Sheehan-Dare, R

    Lasers in surgery and medicine

    2002  Volume 30, Issue 2, Page(s) 135–140

    Abstract: Background and objective: Viral warts affect 7-10% of the population and are a major burden on time and resources of dermatology departments everywhere. Some warts prove resistant to multiple therapies, and this is particularly common in the ... ...

    Abstract Background and objective: Viral warts affect 7-10% of the population and are a major burden on time and resources of dermatology departments everywhere. Some warts prove resistant to multiple therapies, and this is particularly common in the immunosuppressed patient. Numerous treatments are available, but no one treatment has emerged as the treatment of choice. Bleomycin has been shown to be effective in treating warts, but administration can be difficult with risk of local complications. To demonstrate a new technique for easily and safely administrating bleomycin into warts, we undertook an open study to assess the practicality, efficacy, and tolerability of pulsed dye laser immediately followed by intralesional bleomycin in resistant viral hand warts.
    Study design/materials and methods: Ten subjects, all with resistant viral hand warts of at least 3 years duration were recruited. Four subjects were on long-term immunosuppressant drugs. Eighteen warts treated in total. Area of the wart was anaesthetized with 1% lignocaine, then treated with a pulsed dye laser (7 mm spot, fluence 10 J/cm2). Immediately following this bleomycin (0.5 IU/ml) was injected into the base of the wart. Monthly follow-up and treatment until satisfactory clearance.
    Results: Sixteen out of eighteen warts cleared (89%). Eight out of ten warts in the immunosuppressed subjects cleared. The remaining two warts responded partially to two treatments, but the patient was happy with the result and did not wish further treatment. All warts in the immunocompetent subjects cleared. No serious side effects were seen.
    Conclusions: The initial treatment of the wart with pulsed dye laser serves to "prepare" the wart for the bleomycin injection, which can then be given very easily. This ensures the drug is deposited into the base of the wart where it is most needed and minimises the risk of infiltration of normal skin or the operative environment. This method of combining pulsed dye laser and intralesional bleomycin appears to be a safe, rapid, well tolerated, and successful treatment for resistant hand warts. It has proven to be effective in warts in immunosuppressed patients and at difficult sites (e.g., subungual warts). These findings need confirmation from a larger controlled study.
    MeSH term(s) Adult ; Aged ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/therapeutic use ; Bleomycin/administration & dosage ; Bleomycin/therapeutic use ; Combined Modality Therapy/methods ; Dermatologic Agents/administration & dosage ; Dermatologic Agents/therapeutic use ; Drug Resistance, Viral ; Female ; Follow-Up Studies ; Hand/surgery ; Humans ; Injections, Intralesional ; Laser Therapy/methods ; Male ; Middle Aged ; Risk Factors ; Treatment Outcome ; Warts/surgery
    Chemical Substances Anti-Bacterial Agents ; Dermatologic Agents ; Bleomycin (11056-06-7)
    Language English
    Publishing date 2002-01-28
    Publishing country United States
    Document type Clinical Trial ; Journal Article
    ZDB-ID 604493-1
    ISSN 1096-9101 ; 0196-8092
    ISSN (online) 1096-9101
    ISSN 0196-8092
    DOI 10.1002/lsm.10024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top